N

ew York hedge fund Kerrisdale Capital is betting on the failure of Sage Therapeutics’ (SAGE) drug for severe epilepsy with results from a phase 3 clinical trial expected next month.

“We are short Sage going into the trial because nothing has changed from our original thesis,” Kerrisdale founder and Chief Investment Officer Sahm Adrangi told me Friday.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X